Scientific Advances in Lung Cancer 2015

Tsao, Anne S., Scagliotti, Giorgio V., Bunn, Paul A., Carbone, David P., Warren, Graham W., Bai, Chunxue, de Koning, Harry J., Yousaf-Khan, A. Uraujh +29 more·2016·Journal of Thoracic Oncology
DOI 10.1016/j.jtho.2016.03.012

Cites (241)

Items 201–240 of 240

  1. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression
    Sai‐Hong Ignatius Ou, Jeffrey C. Milliken, Michele C. Azada, Vincent A. Miller, Siraj Mahamed Ali, Samuel Jacob Klempner · 2015 · Lung Cancer
  2. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib
    Ling Shan, Peidi Jiang, Feng Xu, Weilong Zhang, Lei Guo, Jian Wu, Yixin Zeng, Yuchen Jiao, Jianming Ying · 2015 · Journal of Thoracic Oncology
  3. Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada
    Sonya Cressman, Stephen C. Lam, Martin Carl Tammemägi, William Kenneth Evans, Natasha B. Leighl, Dean A. Regier, Corneliu Bolbocean, Frances A. Shepherd, Ming‐Sound Tsao, Daria Manos et al. · 2014 · Journal of Thoracic Oncology
  4. The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma
    Darin D. Westaway, Christopher W. Toon, Mahtab Farzin, Loretta Sioson, Nicole Watson, Peter W. Brady, David Marshman, Manu Mathur, Anthony James Gill · 2013 · Pathology
  5. Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis
    Rita Chiari, Giulio Metro, Daniela Iacono, Guido Bellezza, Alberto Rebonato, Alessandra Dubini, Isabella Sperduti, Chiara Bennati, Luca Paglialunga, Marco Angelo Burgio et al. · 2015 · Lung Cancer
  6. Lung cancer and passive smoking
    Allan K. Hackshaw · 1998 · Statistical Methods in Medical Research
  7. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
    Scott Joseph Antonia, Sarah B. Goldberg, Ani Sarkis Balmanoukian, Rachel E. Sanborn, Keith E. Steele, Rajesh Narwal, Paul B. Robbins, Yu Lan Gu, Joyson Joseph Karakunnel, Naiyer A. Rizvi · 2015 · Journal of Clinical Oncology
  8. Screening-Detected Lung Cancers: Is Systematic Nodal Dissection Always Essential?
    Giulia Veronesi, Patrick Maisonneuve, Giuseppe Pelosi, Monica Casiraghi, Bernardo G. Agoglia, Alessandro Borri, Laura Lavinia Travaini, Massimo Bellomi, Cristiano Rampinelli, Daniela Brambilla et al. · 2011 · Journal of Thoracic Oncology
  9. Tumor islands and spread through air spaces: Distinct patterns of invasion in lung adenocarcinoma
    Vicente Morales‐Oyarvide, Mari A. Mino-Kenudson · 2015 · Pathology International
  10. Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC.
    Alice Tsang Shaw, Todd Michael Bauer, Enriqueta Felip, Benjamin Besse, Leonard Philip James, Jill S. Clancy, Ganesh M. Mugundu, Jean‐François Martini, Antonello Abbattista, Benjamin Solomon · 2015 · Journal of Clinical Oncology
  11. Video-Assisted versus Open Lobectomy in Patients with Compromised Lung Function: A Literature Review and Meta-Analysis
    Ruoyu Zhang, Mark K. Ferguson · 2015 · PLoS ONE
  12. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
    Mario Sznol, Harriet M. Kluger, Frank Stephen Hodi, David F. McDermott, Richard D. Carvajal, Donald P. Lawrence, Suzanne Louise Topalian, Michael B. Atkins, John D. Powderly, William Howard Sharfman et al. · 2013 · Journal of Clinical Oncology
  13. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer
    Gail Elizabeth Darling, Fei Li, Demetris Patsios, Christine Massey, Adam Wallis, Linda E. Coate, Shaf H Keshavjee, Andrew F. Pierre, Marc E. de Perrot, Kazuhiro Yasufuku et al. · 2015 · European Journal of Cardio-Thoracic Surgery
  14. RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib
    Sanjay Mukhopadhyay, Nathan A. Pennell, Siraj Mahamed Ali, Jeffrey S. Ross, Patrick C. Ma, Vamsidhar Velcheti · 2014 · Journal of Thoracic Oncology
  15. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    Karen L. Kelly, Julien Mazières, Natasha B. Leighl, Fabrice Barlési, Gérard Zalcman, Michael S. Gordon, Karen L. Reckamp, David R. Gandara, Carlos Gomez‐Roca, Jaafar Bennouna et al. · 2013 · Journal of Clinical Oncology
  16. Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling
    Sai‐Hong Ignatius Ou, Zachary Rockow Chalmers, Michele C. Azada, Jeffrey S. Ross, Philip J. Stephens, Siraj Mahamed Ali, Vincent A. Miller · 2015 · Lung Cancer
  17. Clinical controlled comparison between lobectomy and segmental resection for patients over 70 years of age with clinical stage I non-small cell lung cancer
    Yu Cheng, Chaojun Duan, Siyuan Dong, H. Zhang, S.K. Zhang, S.Q. Wang, C.F. Zhang · 2012 · European Journal of Surgical Oncology
  18. Integration of tobacco cessation services into multidisciplinary lung cancer care: rationale, state of the art, and future directions.
    Graham Walter Warren, Kenneth Daniel Ward · 2015 · PubMed Central
  19. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib
    Oliver Pascal Gautschi, Solange Peters, Vincent Zoete, Franziska Aebersold, Klaus Strobel, Bernhard Schwizer, Astrid Hirschmann, Olivier Alain Michielin, Joachim Diebold · 2013 · Lung Cancer
  20. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).
    Heather A. Wakelee, Suzanne Eleanor Dahlberg, S.M. Keller, David R. Gandara, S. L. Graziano, N. B. Leighl, Alex A. Adjei, Joan H. Schiller, Eastern Cooperative Oncology Group · 2011 · Journal of Clinical Oncology
  21. Lung-MAP--framework, overview, and design principles.
    Renata Ferrarotto, Mary Weber Redman, David R. Gandara, Roy S. Herbst, Vassiliki A. Papadimitrakopoulou · 2015 · PubMed
  22. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
    Sandeep Kodityal, Julia Andrea Elvin, Rachel M. Squillace, Nikita Agarwal, Vincent A. Miller, Siraj Mahamed Ali, Samuel Jacob Klempner, Sai‐Hong Ignatius Ou · 2015 · Lung Cancer
  23. Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).
    David Planchard, Harry J.M. Groen, Tae Min Kim, James R. Rigas, Pierre Jean Souquet, Christina S. Baik, Fabrice Barlési, Julien Mazières, Élisabeth Quoix, C. Martin Curtis et al. · 2015 · Journal of Clinical Oncology
  24. 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
    Rolf A. Stahel, Urania G. Dafni, Oliver Pascal Gautschi, Enriqueta Felip, Alessandra Curioni Fontecedro, Solange Peters, Bartomeu Massutí, Felipe Cardenal, Santiago Ponce-Aix, Martin Früh et al. · 2015 · European Journal of Cancer
  25. Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.
    David R. Gandara, Sandrine Hiret, George R. Blumenschein, Fabrice Barlési, Jean‐Pierre Delord, Jeannick Madelaine, Jeffrey R. Infante, Karen L. Reckamp, Primo N. Lara, Christine Audebert et al. · 2013 · Journal of Clinical Oncology
  26. Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC)
    Joachim von Pawel, Giorgio V. Scagliotti, Silvia Novello, Rodryg Ramlau, Adolfo Gino Favaretto, Fabrice Barlési, Wallace Akerley, С. В. Орлов, Armando Santoro, Frances A. Shepherd et al. · 2014 · Pneumologie
  27. Role of Limited Sublobar Resection for Early-Stage Lung Cancer: Steady Progress
    Hisao Asamura · 2014 · Journal of Clinical Oncology
  28. An Official American Thoracic Society Research Statement: Current Understanding and Future Research Needs in Tobacco Control and Treatment
    Frank T. Leone, Kai‐Håkon Carlsen, Patricia A. Folan, Karen Latzka, Alfred Munzer, Enid Neptune, Smita Sakha Pakhale, David P.L. Sachs, Jonathan M. Samet, Dona J. Upson et al. · 2015 · American Journal of Respiratory and Critical Care Medicine
  29. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC).
    George R. Blumenschein, Egbert Frederik Smit, David Planchard, Dong‐Wan Kim, Jacques L. Cadranel, Tommaso Martino De Pas, Frank Dunphy, Katalin Udud, Myung‐Ju Ahn, Nasser H. Hanna et al. · 2013 · Journal of Clinical Oncology
  30. Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
    Corey Allan Carter, Arun Rajan, Eva M. Szabo, Sean Khozin, Anish Thomas, Christina E. Brzezniak, Udayan Guha, Laurence Austin Doyle, Corrine Keen, Seth M. Steinberg et al. · 2013 · Journal of Clinical Oncology
  31. Current surgical treatment of non-small-cell lung cancer
    Paul E. Van Schil, Jeroen M. Hendriks, Marjan Hertoghs, Patrick Lauwers, Cliff K. C. Choong · 2011 · Expert Review of Anticancer Therapy
  32. Multimodal treatment of non-small-cell lung cancer
    Wilfried Eberhardt, Martin Stuschke · 2015 · The Lancet
  33. Concurrent Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer: What Is the Best Regimen?
    Wilfried Eberhardt · 2015 · Journal of Clinical Oncology
  34. LBA2_PR Afatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7)
    K. Park, E.H. Tan, L. Zhang, Vera Hirsh, Kenneth John O'Byrne, Michael Joseph Boyer, J.C-H. Yang, Tony S.K. Mok, M. Kim, Dan Massey G et al. · 2015 · Annals of Oncology
  35. Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma
    Guido Francini, Roberto Petrioli, Stefano Gonnelli, Pierpaolo Correale, Daniele Pozzessere, Stefania Marsili, Andrea Montagnani, Barbara Lucani, Stefania Rossi, Roberto Di Monaco et al. · 2001 · Cancer
  36. MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer
    A. Drilon, Sai‐Hong Ignatius Ou, Jeffrey William Clark, D. Ross Camidge, Mark A. Socinski, Jared M. Weiss, Benjamin Solomon, Gregory J. Riely, Rebecca Suk Heist, Geoffrey Ira Shapiro et al. · 2017 · Journal of Thoracic Oncology
  37. Targeting the immune system to treat lung cancer: rationale and clinical experience
    Nicolas Marie Guibert, Myriam Delaunay, Julien Mazières · 2015 · Therapeutic Advances in Respiratory Disease
  38. Surgery for oligometastatic disease in non-small-cell lung cancer
    Paul Emile Van Schil, Jeroen M. Hendriks, Laurens Carp, Patrick Lauwers · 2008 · Expert Review of Anticancer Therapy
  39. Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).
    Bartomeu Massutí, Manuel Cobo, José Manuel Rodríguez-Paniagua, Ana Isabel Ballesteros, Teresa Morán, Ricardo Arrabal Sánchez, J.L. González-Larriba, I. Barneto, Y.W. Pun, Javier De Castro et al. · 2015 · Journal of Clinical Oncology
  40. Prospective Phase 2 Clinical Trial of Radiation Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Lung Cancer: An Institutional Trial
    Jeffrey D. Bradley, Feng Gao, Parag Jitendra Parikh, Michael Charles Roach, Sana Saif Ur Rehman, Rojano Kashani, Jehan Ganachaud, Jacob Stroud, Todd A. DeWees, Clifford G. Robinson · 2015 · International Journal of Radiation Oncology*Biology*Physics